Nurix Therapeutics
NRIX
119 hedge funds and large institutions have $462M invested in Nurix Therapeutics in 2022 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 46 increasing their positions, 34 reducing their positions, and 13 closing their positions.
34,920% more call options, than puts
Call options by funds: $1.75M | Put options by funds: $5K
35% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 34
31% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 13
1% more funds holding
Funds holding: 118 → 119 (+1)
1.01% less ownership
Funds ownership: 91.52% → 90.52% (-1%)
18% less capital invested
Capital invested by funds: $561M → $462M (-$98.8M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$8.46M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$7.13M |
| 3 |
BlackRock
New York
|
+$5.06M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$3M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$2.57M |
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.23M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$6.76M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$6.57M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$4.25M |
| 5 |
Goldman Sachs
New York
|
-$2.45M |
NRIX Hedge Fund Activity: Q4 2022 in Review
119 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Nurix Therapeutics (NRIX) for Q4 2022, worth a combined $462M — down 18% from $561M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new NRIX positions and 13 closed out — a net gain of 4 holders — while 46 added to existing stakes and 34 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $8.46M. The largest seller was Fidelity Investments, cutting an estimated $8.23M.
- 119 institutional investors held Nurix Therapeutics (NRIX) as of Q4 2022, up from 118 in Q3 2022.
- Funds reported $462M of Nurix Therapeutics stock for Q4 2022, down 18% quarter-over-quarter.
- 17 funds opened new Nurix Therapeutics positions in Q4 2022 and 13 closed out, a net change of +4 holders.
- The largest Nurix Therapeutics buyer in Q4 2022 was ARK Investment Management, an estimated $8.46M added.
- The largest Nurix Therapeutics seller in Q4 2022 was Fidelity Investments, an estimated $8.23M sold.
Based on aggregated 13F filings for Q4 2022.